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Abstract. 
Background: Overexpression of DNA 5’-cytosine-methyltransferases (DNMTs), which silence 
genes including tumor suppressor genes, is involved in many cancers. However, the mechanism 
of DNMT overexpression remains mostly unclear.  
Objectives: The tumor suppressor p53 and RB proteins, which repress gene transcription, are 
often inactivated by gene mutation or overexpression of the E3 ubiquitin ligase MDM2 in can-
cer cells. Therefore, this study aims to examine whether the transcriptional regulation of 
DNMT1, 3A and 3B genes is controlled by p53/RB/MDM2 pathway in lung cancer using cell 
and clinical studies.  
Methods: The interaction and regulation between p53 or RB with DNMT1, 3A and 3B promot-
ers were detected by promoter activity assay and chromatin immunoprecipitation. Transcrip-
tional repression of DNMT1, 3A and 3B by p53 and RB was confirmed using siRNA-mediated 
knockdown or overexpression of p53/RB. Immunohistochemistry for p53, RB, MDM2, and 
DNMTs protein expression and DNA sequencing for p53 mutation were performed on tumor 
tissues from lung cancer patients.  
Results: p53 and RB suppressed the promoter activity and mRNA/protein expression of 
DNMT1, 3A and 3B through binding to their promoter. The suppression could be attenuated by 
knocking down of RB and p53. Importantly, co-transfection of both p53 and RB expression 
constructs showed additional inhibition of DNMT protein expression. In clinical study, func-
tional RB and p53 inversely correlated with DNMT1, 3A and 3B expressions in samples from 
lung cancer patients (P=0.016~0.024). Lung cancer patients with low RB expression or p53 
mutation resulting in DNMTs overexpression showed promoter hypermethylation in multiple 
tumor suppressor genes. Patients with normal expression of DNMT3A, RB and MDM2 was 
associated with better prognosis compared to other patients (P=0.049). 
Conclusions: This study provides cell and clinical evidence that p53 and RB pathways tran-
scriptionally repress DNMT expression. Normal expression of DNMT3A, RB and MDM2 pro-
teins can be a biomarker for good prognosis in lung cancer. 
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中文摘要 
背景：抑癌基因的啟動子被過度甲基化時，會導致基因不表達進而使腫瘤生成；此甲基
化現象主要是由 DNA 甲基轉移酵素（DNA methyltransferases，DNMTs）所調控，DNMTs
主要有 DNMT1、DNMT3A 以及 DNMT3B，文獻指出，在很多癌症中發現 DNMTs 有過
度表達的情形，然而造成此現象的詳細機制仍不清楚。 
目的：文獻顯示 p53 及 RB 抑癌蛋白可以負調控許多基因表現，其上游蛋白 MDM2 則可
抑制 p53 及 RB 蛋白表現，因此本篇研究以肺癌細胞及臨床模式探討 p53/RB/MDM2 調控
路徑參與 DNMT 其轉錄調控異常之機制。 
方法：在細胞層次上，由報導基因冷光酵素活性分析（luciferase assay）與染色質免疫沈
澱（chromatin immunoprecipitation）觀察抑癌蛋白 p53 及 RB 是否對 DNMTs 扮演負轉
錄調控因子的角色。在臨床研究上，以免疫組織染色法（immunohistochemistry）及 DNA
定序分析非小細胞肺癌病人組織中 DNMT 與 RB 蛋白及 p53 突變之相關性。 
結果：在癌細胞株中大量表現 p53 及 RB 後，會抑制 DNMT1 及 DNMT3A 啟動子的活性
及 mRNA 表現量；以 siRNA 降低 p53 及 RB 的表現量後，DNMT1 及 DNMT 3A 啟動子的
活性及 mRNA 表現量上升，顯示 p53 及 RB 的確能負轉錄調控 DNMT3A 的基因表現。在
臨床研究上，以免疫組織染色法及 DNA 定序分析 100 位非小細胞肺癌病人組織，發現
DNMT1、DNMT3A 及 DNMT3B 蛋白過度表現且 RB 蛋白低表現或 p53 突變有顯著負相關
性（P 值為 0.016～0.024），且其抑癌基因多為啟動子過度甲基化；此外，病人存活率分析
資料指出：DNMT3A、RB 與 MDM2 蛋白皆正常表現的病人，與其他病人相較，有較好的
預後（P 值為 0.049）。 
結論: 由以上細胞及臨床模式實驗結果顯示，p53 及 RB 蛋白會負轉錄調控 DNMT 的啟動
子，進而降低 DNMT 的 mRNA 及蛋白質表現，但此 p53 及 RB 轉錄負調控 DNMT 的作用
可被 MDM2 蛋白所拮抗。臨床資料顯示 DNMT3A、RB 與 MDM2 蛋白的表現程度可做為
肺癌病人預後的指標。 
 
關鍵字: DNA 甲基轉移酵素、p53、RB、轉錄調控、肺癌 
 
INTRODUCTION 
Lung cancer is one of the most common malignan-
cies in the world and is the leading cause of cancer- 
related deaths in industrial countries [1]. It has long 
been known that the cancer cells undergo changes in 
distribution of 5’-methylcytosine modifications in-
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cluding the region-specific hypermethylation of pro-
moter CpG islands associated with tumor suppressor 
genes (TSGs) [2]. Aberrant promoter hypermethyla-
tion of CpG islands in TSGs leads to transcriptional 
repression and results in tumorigenesis. DNA methyl-
ation is accomplished by DNA methyltransferases 
(DNMTs). DNMT1 is a “maintenance” methyltrans-
ferase and is the primary enzyme responsible for 
keeping methylation patterns after DNA replication. 
DNMT3A and 3B are responsible for the de novo 
methylation that has been shown to play crucial roles 
in embryonic development, genomic imprinting and 
transcriptional silencing [3,4]. Recent study showed 
that DNMTs played an essential role in tumorigenesis 
through methylating promoters of several TSGs [5]. 
We have previously demonstrated that the up-regulation 
of DNMT1, 3A and 3B mRNA or protein expression 
levels in non-small cell lung carcinoma (NSCLC) [6]. 
Overexpression of DNMT1, 3A and 3B is also sug-
gested to be associated with poor prognosis in NSCLC 
patients [6,7]. However, the mechanism of overex-
pression of DNMT1, 3A and 3B remains unclear in 
many cancers. 
In our previous study, the DNMT1, 3A and 3B 
proteins were found to be overexpressed in NSCLC in 
a coordinate manner [6], suggesting a common regu-
latory pathway for expression of DNMT genes. The 
DNMT1 promoter has been found to contain E2F 
binding sites that are required for RB/E2F regulation 
[8,9]. The tumor suppressor RB protein represses gene 
transcription, required for transition from G1 to S 
phase, by directly binding to the transactivation do-
main of E2F as a complex on the promoters of the 
E2F targeted genes [10,11]. The RB protein has been 
found to be inactivated by gene deletions, mutation 
and protein phosphorylation in lung cancer [10]. In 
addition, we previously reported that DNMT1 was 
transcriptionally suppressed by p53 in NSCLC pa-
tients and cell lines [12]. Therefore, it is worthy to 
analyze whether RB and p53 are involved in tran-
scriptional regulation of DNMT genes in cancer cells 
and NSCLC patients. 
Note that MDM2, an E3 ubiquitin ligase for p53, 
also physically interacts with RB resulting in ubiqui-
tin-proteasome-mediated degradation of RB [13,14]. 
Overexpression of MDM2 has been demonstrated in 
many human cancers [15]. Therefore, our study fur-
ther examined whether MDM2 plays a critical role in 
regulating the DNMT genes by synergistically destabi-
lizing both RB and p53 proteins and analyzed the re-
lationship of MDM2 protein with RB, p53 and 
DNMTs proteins in NSCLC cells and patients. 
 
METHODS  
 
Cell Lines 
All cell lines used in this study were purchased 
from American Type Culture Collection. The A549 
(RB/p53 wild-type) and H1299 cell line (RB wild- 
type, p53 null) were derived from NSCLC tumors, 
and the 5637 cell line (RB null, p53 mutant) was de-
rived from a human bladder carcinoma.  
 
Plasmid, RNAi and Transfection 
The plasmids and interference RNA (RNAi) used 
in the study were from Invitrogen Inc.  Plasmids and 
RNAi transfections were carried out with lipofetamine 
2000 (Invitrogen, Carlsbad, CA, USA) according to 
the manufacturer’s protocol. 
 
Reverse-transcriptase Polymerase Chain 
Reaction (RT-PCR) Assay 
The primers used for RT-PCR and quantitative 
RT-PCR analyses were described previously [12,16]. 
To quantify the relative levels of mRNA expression in 
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the RT-PCR assay, the value of the internal standard 
(β-actin) in each reaction was used as the baseline 
gene expression of that sample and the relative value 
was calculated for the target genes for cancer cells. 
The cycle number, amount of primers and cDNA used 
were determined to provide quantitative amplification 
during multiplex RT-PCR. 
 
Western Blot 
The cells lysates were centrifuged at 13,000 r.p.m. 
for 10 min at 4°C, SDS gel loading buffer was added 
and samples containing equal amounts of protein (50 
µg) were separated on an 6% SDS-PAGE then elec-
tro-blotted onto Immobilon-P membranes (Millipore 
Co., Bedford, MA, USA) in transfer buffer. Im-
munoblotting was performed with antibodies against 
DNMT1, DNMT3A, RB, p53, and β-actin. Each 
Western analysis was repeated three times. 
 
Chromatin Immunoprecipitation 
(ChIP)-PCR Assay 
Cell lysates were cross-linked with 1% formalde-
hyde for 15 min at 37°C and stopped by the addition 
of glycine to a final concentration of 0.125 M. Lysates 
were sonicated on ice to shear DNA to lengths be-
tween 200 and 800 bp. Subsequent steps were per-
formed with the ChIP assay kit (Upstate, Millipore, 
Billerica, MA, USA) according to the manufacturer's 
instructions. Chromatin was immunoprecipitated for 
16 h at 4°C using anti-p53 antibody. PCR analysis for 
immuno-complexes of the isolated DNA fragments 
were performed using the primers for the DNMT1 
(-19~+317) and DNMT3A (-450~-127) promoters de-
scribed previously [12,16]. For quantitative ChIP-PCR, 
total input served as an internal control. Relative 
quantitation using the comparative Ct method with the 
data from ABI PRISM 7000 (version 1.1 software) 
was performed according to the manufacturer's proto-
col. 
 
 
Quantitative Methylation-specific PCR 
(MSP) 
The promoter methylation status of the RASSF1A, 
hRAB37, FHIT, p16, and RARβ genes was determined 
by chemical treatment with sodium bisulfite followed 
by MSP analysis. Primer sequences were described 
previously [12,16]. All PCRs were performed with 
positive controls for both unmethylated and methyl-
ated alleles and no DNA control during MSP assay. 
For quantitative MSP, β-actin serves as an internal 
control. Relative quantitation using the comparative 
Ct method with the data from ABI PRISM 7000 was 
performed according to the manufacturer's protocol. 
 
Study Population 
Surgically resected tumor samples from 100 pa-
tients diagnosed with primary NSCLC admitted to 
Veterans General Hospital, Taichung and Taipei, were 
collected between 1993 and 2007 after obtaining ap-
propriate institutional review board permission and 
written informed consent from the patients. The end of 
the follow-up period was defined as July 2010 for all 
patients. 
 
Immunohistochemistry (IHC) Assay 
Paraffin blocks of tumors were sectioned into 5 
um slices and then processed using standard tech-
niques. Antibodies and their experimental conditions 
were performed as previously described [6,12,16]. 
The evaluation of the IHC staining was conducted 
blindly, without prior knowledge of the clinical and 
pathologic characteristics of the cases. The surround-
ing non-neoplastic stroma served as an internal nega-
tive control for each slide. Staining was scored as +++ 
if >75% tumor cells were immunostaining-positive; 
++ for 50-75%; + for 25-50%; +/– for 10-25% cells 
and – if <10% were positive. For DNMT1, DNMT3A 
or MDM2 protein expression level, the stains were 
graded as “overexpression” if the score were ++ and 
+++. For RB protein expression level, the stains were 
graded as “low expression” if the score was +/– or –. 
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Staining for wild-type p53 was scored as +++ if >50% 
tumor cells were immunostaining-positive; ++ for 
26-50%; + for 11-25%; and – if <10% cells were posi-
tive. The stains were graded p53 overexpression if the 
score was ++ or +++. 
 
p53 Mutation Assay 
Tumors were analyzed for sequence alterations of 
p53 gene as described previously [17]. 
 
Statistical Analysis 
The Fisher's exact test was used to compare the 
protein expression levels of DNMT1, DNMT3A or 
DNMT3B with those of RB and MDM2 as well as 
p53 mutation between NSCLC patients. Type III cen-
soring was performed on subjects who were still alive 
at the end of the study. Overall survival curves were 
calculated according to the Kaplan-Meier method, and 
comparison was performed using the log-rank test. P 
< 0.05 was considered to be statistically significant. 
 
RESULTS 
 
The Correlation between p53 Mutation, 
RB Alteration and DNMT  
Overexpression  
It has been shown that p53 appears to repress 
transcription from the DNMT1 promoter in NSCLC 
cell line [12] and an increase of DNMT1 expression 
occurs in the Rb-/- mouse cells [9]. Therefore, we 
examined the correlation of overexpression of DNMT 
proteins with p53 gene mutation and RB expression in 
100 lung tumors (Table 1). The data indicated that the 
p53 gene mutation was significantly associated with 
DNMT1 protein overexpression (P=0.024) and 
DNMT3A protein overexpression (P=0.021). This 
association was significant especially in those patients 
with promoter hypermethylation in multiple TSGs 
(P=0.005 for DNMT1, P=0.015 for DNMT3A). In 
addition, the low expression of RB was significantly 
associated with DNMT protein overexpression 
(P=0.021) and was especially strong in smoker (P= 
0.003) and squamous cell carcinoma (SCC) (P=0.013) 
patients with DNMT1 overexpression and hypermeth-
ylation in multiple TSG promoters. Notably, patients 
with p53 mutation and low RB expression often had 
overexpression of DNMT1 (P = 0.016). However, 
DNMT3B protein overexpression did not show corre-
lation with p53 gene mutation and RB expression in 
all patients or stratified patients analyzed. 
 
Wild-type p53 Represses DNMT1 and 
DNMT3A Promoter Activity and mRNA 
Expression Level 
We have recently reported that DNMT1 is tran-
scriptionally suppressed by p53 [12]. Therefore, we 
investigated whether p53 is also involved in the tran-
scriptional regulation of DNMT3A gene. A dual lucif-
erase assay to quantify the regulation of DNMT3A 
gene by ectopically expressed p53 in H1299 lung 
cancer cells was performed by co-transfecting pGL4- 
luciferase and pGL4-DNMT3A promoter-reporter 
plasmids. The ectopically expressed wild-type p53 
suppressed DNMT3A promoter activity in a dose-  
dependent manner (Figure 1A). ChIP-PCR assay 
showed the binding of p53 to the DNMT3A promoter 
in normal lung tissues and H1299 cells ectopically 
expressing p53 (Figure 1B). The quantitative RT-PCR 
confirmed that exogenous expression of wild-type p53 
suppressed the DNMT3A mRNA expression in H1299 
cells (Figure 1C, upper panel). In addition, knock-
down of endogenous wild-type p53 in A549 cells in-
creased the DNMT3A mRNA level (Figure 1C, lower 
panel), suggesting that p53 can transcriptionally re-
press the DNMT3A expression. 
 
RB Negatively Regulates the Expression 
of DNMT1 and DNMT3A Genes Leading 
to Decrease of Methylation Level  
Globally and TSG Specifically 
The RB has been reported to down-regulate 
DNMT1 promoter activity in murine epithelial and  
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Table 1. The correlation between DNMT protein overexpression and p53 mutation and RB low expression 
in NSCLC patientsa 
Characteristics 
   DNMT1     DNMT3Ab     DNMT3B   
Total n  (%) n  (%) n  (%) 
Overall 100 45 (45.0) 23 (32.4) 31 (31.0) 
    
p53 gene        
 Mutation 28 18 (64.3)0.024 10 (55.6)0.021 9 (32.1) 
 Wild type 72 27 (37.5) 13 (24.5) 22 (30.6) 
 
When p53 gene mutation 
 Smoker Yes 18 13 (72.2) 8 (72.7)0.003 6 (33.3) 
  No 3 2 (66.7) 0 (0.0) 1 (33.3) 
      
 Tumor typed SCC 17 12 (70.6) 7 (70.0)0.011 7 (41.2) 
  ADC 9 6 (66.7) 3 (50.0) 2 (22.2) 
    
 More TSGs promoters hypermethylationc     
     
  Hypermethylated 16 14 (87.5)0.005 7 (70.0)0.015 6 (37.5) 
   Normal 12 4 (33.3) 3 (37.5) 3 (25.0) 
    
RB protein         
 Normal expression 43 14 (32.6) 9 (27.3) 10 (23.3) 
 Low expression 50 29 (58.0)0.021 13 (35.1) 20 (40.0) 
 
When RB low expression 
 Smoker Yes 25 20 (80.0)0.003 7 (43.8) 10 (40.0) 
  No 19 7 (36.8) 4 (25.0) 7 (36.8) 
      
 Tumor typed SCC 17 14 (82.4)0.013 5 (45.5) 8 (47.1) 
  ADC 31 14 (45.2) 8 (32.0) 12 (38.7) 
    
 More TSGs promoters hypermethylation     
     
  Hypermethylated 24 17 (70.8)0.093 8 (47.1) 11 (45.8) 
  Normal 26 12 (46.2) 5 (25.0) 9 (34.6) 
     
When p53 mutaion and RB low expression 
 DNMT expression 17       
  Overexpression  14 (82.4)0.016 5 (45.5) 6 (35.3) 
  Normal expression  3 (17.6) 6 (54.5) 11 (64.7) 
a. These results were analyzed by the Fisher’s exact test. The P values with significance were shown as superscripts 
b. DNMT3A protein expression was examined in 71 patients who had histological slide available 
c TSG alteration was defined as patient with more than two TSGs showed promoter hypermethylation 
d SCC: squamous cell carcinoma, ADC: adenocarcinoma 
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Figure 1. DNMT3A gene was transcriptionally repressed by p53. (A) Dual luciferase 
assay showed the down-regulation of DNMT3A promoter activity by ectopi-
cally expressed p53 in H1299 cells compared to control vector. (B) 
ChIP-PCR for p53 binding to DNMT3A promoter region in the normal lung 
tissue but not in the p53 null H1299 lung cancer cell (upper). Binding of p53 
can be seen in p53 ectopically expressing H1299 cells (lower). DNMT1, 
known to be bound by p53, serves as positive control. “IgG” is a negative 
control and “No” means absence of antibody. (C) Quantitative RT-PCR anal-
ysis showed the decreased in DNMT3A mRNA expression by overexpression 
of p53 in H1299 cells. Knockdown of p53 (si-p53) dramatically induced 
DNMT3A mRNA expression compared to the si-control in A549 cells. Ex-
periments were performed at least three times. Results from one representa-
tive experiment are shown. Quantitative data are presented as mean ± SD. P 
values are as indicated 
 
 
human osterosarcoma cells [8,9]. To test whether RB 
can also modulate the DNMT3A promoter activity, a 
dual luciferase assay was performed to quantify the 
regulation of DNMT3A and DNMT1 genes by RB in 
5637 bladder cancer cells (RB null). The 5637 cells 
were transiently co-transfected with pGL4-renilla, 
either DNMT1 or DNMT3A promoter-reporter con-
structs, and pCMV-SPORT6 empty vector or pCMV- 
SPORT6-RB (RB). The data indicated that ectopically 
expressed RB decreased both DNMT1 and DNMT3A 
promoter activities (Figure 2A).  
To elucidate whether the endogenous expression of  
20 Y. A. Tang et al./JCRP 1(2014) 14-27
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. RB-mediated repression of DNMT1 and DNMT3A expression leads to reduction in promoter methyla-
tion of multiple TSGs. (A) Dual luciferase assay showed the downregulation of DNMT1 and DNMT3A 
promoter activity by ectopically expressed RB in 5637 cells compared to control vector. (B) RT-PCR 
expression analysis of 5637 and H1299 showed the reduction in endogenous DNMT1 and DNMT3A 
mRNA expressions by RB overexpression. Knockdown of RB (si-RB) dramatically induced endoge-
nous mRNA expression of DNMT1 and DNMT3A compared to the si-control in H1299 cells. (C) West-
ern blot analysis showed the repression of DNMT1 and DNMT3A protein expression by ectopically 
expressed RB in 5637 and H1299 cells. (D) Quantitative MSP assays for hypermethylation status in the 
RARβ FHIT, and RASSF1A promoters in cells overexpressing RB or with RB knockdown are shown. 
(E) MSP analyses for five TSGs including p16, RARβ, FHIT, RASSF1A, and hRAB37 in lung cancer 
patients. Methylation phenotype of TSG was defined as having more than two TSGs showing promoter 
hypermethylation (black bar). Experiments were performed at least three times. Results from one rep-
resentative experiment are shown. Quantitative data are presented as mean ± SD. P values are as indi-
cated 
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Figure 3. Ectopic expression of both RB and p53 to-
gether showed additional repressive effect on 
DNMT3A protein expression by Western 
blotting analysis. Experiments were per-
formed at least three times. Results from one 
representative experiment are shown 
 
 
DNMT3A and DNMT1 genes can be regulated by RB in 
various cell models, we examined the DNMT3A and 
DNMT1 mRNA expression by RT-PCR and protein 
levels by Western blot in A549 and H1299 human 
lung cancer cells (RB wild-type) and 5637 bladder 
cancer cells (RB null). The data indicated that the ec-
topically expressed RB down-regulated the mRNA 
expression (Figure 2B) and protein expression (Figure 
2C) of DNMT3A and DNMT1. To further confirm the 
transcriptional effects of RB on DNMT promoters, we 
transfected H1299 cells, which have a wild-type RB 
background, with siRNA directed against RB and 
found that knockdown of RB induced higher 
DNMT3A and DNMT1 mRNA (Figure 2B) and protein 
expression (Figure 2C) than transfection of si-control, 
confirming the negative transcriptional effects of RB 
on DNMT genes. 
DNMTs are enzymes that methylate the cytosine 
residue of CpGs of the genome and in promoters of 
genes including TSGs. To determine if the level of 
DNMTs in cell manipulating for RB correlated with 
the methylation level of TSGs known to be involved 
in lung tumorigenesis, we analyzed the methylation of 
RARβ, FHIT, and RASSF1A genes which have been 
shown to be frequently hypermethylated in lung can-
cer [18-21] using the quantitative MSP assay. The 
methylation level decreased when RB was overex-
pressed in 5637 cells (RB null), whereas increase of 
methylation was observed when RB was knocked- 
down in H1299 cells (RB wild-type) (Figure 2D). We 
further performed methylation analyses for five TSGs 
including p16, RARβ, FHIT, RASSF1A, and hRAB37 
genes in lung cancer patients. The data indicated that 
low expression of RB and DNMT3A overexpression 
resulted in multiple TSGs hypermethylation in lung 
cancer patients (P = 0.040) (Figure 2E). These data 
confirmed that RB is a transcriptional repressor of 
DNMT1 and DNMT3A genes and RB low expression 
correlates with hypermethylation in multiple TSGs. 
 
RB and p53 Show Additional Repressive 
Effect on DNMT3A Protein Expression 
It has been reported that MDM2 interacts with 
both RB and p53 to promote proteasome-dependent 
protein degradation [13,14,22,23]. Since both p53 and 
RB can be controlled by MDM2, an alteration in both 
p53 and RB pathways could have a synergistic or an 
additional effect on the up-regulation of DNMT3A. 
Such an effect was examined in cell models. Western 
blot results indicated that co-transfection of both p53 
and RB expression constructs showed additional inhi-
bition of DNMT3A protein expression (Figure 3). 
 
Overexpression of DNMTs, Multiple 
TSGs Methylation, and Alteration of the 
Rb/p53/MDM2 Pathway in Lung Cancer 
Patients 
To analyze the correlation between DNMTs pro-
tein overexpression and low expression of RB protein 
in lung cancer patients, immunohistochemistry for 
DNMTs was performed on tumor tissue slide from 
lung cancer patients. An inverse correlation was found  
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Figure 4. Expression of DNMT1, DNMT3A, RB, p53, and MDM2 proteins and analysis of methylation status 
and Kaplan-Meier survival curves in surgically resected NSCLC tumors. (A) Immunohistochemical 
analysis of DNMT1, DNMT3A, RB, wild-type p53, and MDM2 proteins in two representative samples 
from patients is shown. DNMT1 and DNMT3A positive immunoreactivity (+), RB negative immuno-
reactivity (–), wild-type p53 negative immunoreactivity (–), and MDM2 positive immunoreactivity (+) 
were found in patient 1, whereas patient 2 shows the reverse pattern. (Original magnification 200). (B) 
MSP analyses for five TSGs including p16, RARβ, FHIT, RASSF1A, and hRAB37 in lung cancer pa-
tients. Methylation phenotype of TSG was defined as having more than two TSGs showing promoter 
hypermethylation (red bar). (C) The patients with DNMT1 overexpression and RB low expression 
showed poorer overall survival than other patients. Overexpression of DNMT1 was defined as “+”; low 
or negative expression of RB protein was defined as “–”. (D) The patients with normal expression of 
DNMT3A along with normal expression of RB and MDM2 showed better overall survival than other 
patients. Normal expression of DNMT3A, RB or MDM2 was defined as non-overexpression. P value 
for each analysis is as indicated 
 
 
between RB with DNMT1 and DNMT3A protein ex-
pressions in lung cancer patients (Figure 4A). In addi-
tion, DNMT1 and DNMT3A protein overexpression 
was found to be associated with the loss of functional  
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Figure 5. Model for the transcription regulation mediated by p53/RB/MDM2 on DNMT promot-
ers. (A) RB and E2F1 bind on the DNMT promoter and negatively regulate DNMT gene 
expression, lead to repression of DNMT mRNA and protein expression levels. This 
negative regulation can be enhanced by p53 expression. (B) Transcriptional repression 
of DNMT expression by RB/E2F1 and p53 pathways can be diminished by MDM2 
overexpression through ubiquitination-mediated degradation of both RB and p53 pro-
teins 
 
 
p53 manifested by p53 gene mutation (Figure 4A, 
Table 1). Moreover, overexpression of MDM2 in lung 
cancer patients was associated with low expression of 
RB and non-overexpressed wild-type p53 protein, and 
was positively correlated with DNMT1 and DNMT3A 
protein expression (Figure 4A). In addition, MDM2 
overexpression correlated with hypermethylation in 
multiple TSGs in lung cancer patients (P = 0.058) 
(Figure 4B). 
 
 
The Prognostic Effects of 
DNMT1/DNMT3A Overexpression in 
Relation to RB and MDM2 Expression 
To define the prognostic effects of DNMTs over-
expression in lung cancer patients, survival curves 
were estimated using the Kaplan-Meier method. The 
data indicated that patients with DNMT1 overexpres-
sion and low expression of RB showed significantly 
poor post-operative overall survival than other patients 
(P = 0.007, Figure 4C). Importantly, NSCLC patients 
with normal expression on tested proteins including 
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DNMT3A, RB and MDM2 was associated with better 
prognosis compared to other patients (P = 0.049, Fig-
ure 4D).  
 
DISCUSSION 
During lung tumorigenesis, overexpression of the 
three major functional DNMTs (DNMT1, DNMT3A, 
and DNMT3B), which catalyze cytosine methylation, 
is important for silencing TSGs and leads to cancer 
formation and poor prognosis. In our previous study, 
the protein of DNMT1, 3A, and 3B were highly ex-
pressed in lung tumor samples in a coordinate manner 
[6], suggesting a common regulatory pathway for 
DNMT gene expression. The current study shows a 
link between overexpression of DNMTs and alteration 
of RB and p53 in lung cancer through interactions of 
RB and p53 with DNMT3A and DNMT1 promoters. 
Our cellular and clinical results reveal a mechanism of 
RB and p53-mediated transcriptional repression of 
DNMT1 and DNMT3A expression and this regulation 
can be attenuated by MDM2 expression. To our 
knowledge, this is the first clinical correlation and 
prognostic study on alterations of both DNMT3A and 
DNMT1 in the same series of cancer patient cohort for 
dysregulation of p53/MDM2 and RB/MDM2 path-
ways.  
We provided evidence for an additional repressive 
effect of RB and p53 on DNMT3A and DNMT1 in 
various human cancer cell lines (Figure 1, Figure 2) 
and surgically resected lung tumors (Table 1, Figure 4). 
Note that our previous study showed a low expression 
of MDM2 contributes to accumulation of the 
wild-type p53 [17] so the antibody which recognizes 
only the wild-type of p53 protein was used to identify 
the status of overexpressed p53 in IHC assays (Figure 
4). The promoter luciferase reporter assay and Western 
blot analysis also suggested that promoter activity and 
endogenous protein expression level of DNMT3A and 
DNMT1 could be repressed by RB and further rein-
forced by p53 expression (Figure 1, Figure 2, Figure 
3). Therefore, DNMTs expression is negatively regu-
lated by both RB and p53 at the transcriptional level. 
Importantly, as an E3 ubiquitin ligase, MDM2 has 
been reported to control protein stability of both p53 
and RB [13,14,22,23]. The significant positive rela-
tionship of DNMTs and MDM2 shown in clinical pa-
tients (Figure 4) may be caused by the synergistic 
degradation of RB and p53 and/or other transcription 
factors by MDM2. Moreover, the patients with 
MDM2 overexpression showed methylation in multi-
ple TSGs (Figure 4B). These data suggested that the 
loss of RB protein and/or p53 protein coordinately by 
defective MDM2 control raises the risk of promoter 
hypermethylation in TSGs through diminishing the 
repression on DNMT promoters.  
Recent evidence show that DNMT1 may work to-
gether with DNMT3A and DNMT3B in “de novo” 
methyltransferase activity in certain genome regions 
in both embryonic cells and differentiated somatic 
cells [24,25]. In this study, we showed that manipula-
tion of DNMT1 and DNMT3A in lung cancer cells by 
RB overexpression or knockdown resulted in con-
cordant changes in the methylation level in the pro-
moters of multiple TSGs in cell models (Figure 2D) 
and lung cancer patients (Figure 2E). These observa-
tions imply that DNMT1 and DNMT3A could coor-
dinately methylate and silence a subset of TSGs, 
which are important genes involved in lung tumor-
igenesis. However, whether different DNMTs act 
alone or cooperatively with each other to maintain 
DNA methylation pattern in human cancer remains 
unclear. Thus, interrogation of genome-wide distribu-
tion of DNMTs in cancer cell will be needed to dis-
close the precise mechanism by which DNMTs par-
ticipate in tumorigenesis. 
Overexpression of DNMTs plays a causative role 
in tumorigenesis. Several disruptive mechanisms that 
control the expression of DNMTs have been reported. 
For example, viral infection activates DNMT1 through 
the RB pathway [26]. The mammalian-specific miR- 
290 cluster and Kaposi’s sarcoma-associated herpes-
virus miRNA, K12-4-5p, enhance the expression of 
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DNMT1, DNMT3A, and DNMT3B via silencing 
RB-like 2 protein [27,28]. Several human miRNAs, 
including miR-29 family, miR-148, and miR-143 have 
been found to be frequently downregulated in human 
cancers and lead to increase expression of DNMT1, 
DNMT3A or DNMT3B because they directly target 
the 3’-UTR of DNMTs [7,29,30].  
The present study adds a new dimension to our 
understanding of DNMTs overexpression in cancer 
cells (Figure 5). We elucidate that the MDM2 targets 
both RB and p53 for degradation, thus interfering with 
the repression of DNMT genes, and resulting in 
DNMTs overexpression in cancer cells. Moreover, 
increased protein expressions of DNMT1 and 
DNMT3A are associated with insufficient transcrip-
tional repression by low RB expression and p53 muta-
tion in NSCLC patients. Notably, some specific mu-
tant p53 proteins are identified that would abolish the 
repression on many target genes. For example, p53 
mutants on codons 248 and 273 show a significantly 
stronger dominant-negative effect over wild-type p53 
[31]. Whether overexpression of DNMTs resulted 
from the loss of transcriptional repression of mutant 
p53 is needed for further clarification. The DNMTs 
overexpression causes abnormal 5’CpG hypermethyl-
ation in various TSGs, and ultimately leads to poor 
prognosis of affected patients. MDM2 is frequently 
overexpressed in various cancers [15]. Our study pro-
vides rationale for developing drugs targeting DNMTs 
and MDM2 to reverse the aberrant epigenetic status 
for anti-cancer therapy. 
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